生物標記交易：合約價值與趨勢（2019-2025）

本報告對全球生物標記市場的策略交易（包括許可、收購和合作）進行了分析。

它重點關注2019年至2025年期間執行的交易，對交易活動進行回顧性評估，以確定生物標記領域的新興趨勢、投資行動和策略重點。

調查範圍

這份名為《生物標記交易：交易價值與趨勢（2019-2025）》的報告全面分析了全球生物標記產業的策略交易，包括授權、收購和合作。報告重點關注2019年至2025年期間達成的交易，並對交易活動進行回顧性評估，以識別生物標記領域的新興趨勢、投資行動和策略重點。

為了識別生物標記產業的新興趨勢、投資行為和策略重點，本報告重點關注2019年至2025年期間達成的交易，反映交易條款、交易價值和交易結構等方面的實際情況。報告透過實際案例，對交易條款進行調查分析，包括預付款、里程碑式薪酬、特許權使用費安排和終止條款。

除了交易分析之外，本報告還深入回顧了影響生物標記開發和商業化市場的市場動態，強調了市場促進因素、限制因素、機會和挑戰，以及該領域的新興技術。

總體而言，本報告為尋求了解生物標記夥伴關係現狀的潛在交易商提供了寶貴的資源。它提供了企業如何合作研究、開發和商業化生物標記技術的可行見解，幫助他們在這個快速發展的領域中做出明智的決策。

報告內容

• 生物標記產業現狀概述、近期的授權協議、市場合作和收購
• 本報告涵蓋影響生物標記市場發展的關鍵公司、趨勢、障礙和其他資訊。
• 回顧市場中的交易條款，重點關注關鍵交易趨勢、包括的公司，並進一步分析潛在的許可、合作和收購機會
• 為潛在交易商提供有關生物標記技術和產品研發和商業化合作的重要訊息
• 有關生物標記行業許可、收購和合作交易的關鍵要素的資訊
• 三角測量方法調查方法和重要細節，例如專利研究和分析、臨床試驗研究和分析
• 不同類型的生物標記交易、里程碑付款的詳細資訊及其在各種交易中的價值
• 生物標記專利格局分析
• 主要企業，包括Thermo Fisher Scientific Inc.、F. Hoffmann-La Roche Ltd.、Illumina Inc.、Bio-Rad Laboratories Inc. 和Agilent Technologies Inc.。

目錄

第1章 執行摘要

第2章 市場概況

• 概述
• 生物標記分類
• 生物標誌範例

第3章 市場動態

• 概述
• 市場促進因素
• 疾病發病率上升
• 體學和成像技術的進展
• 市場限制
• 開發成本
• 對技術純熟勞工的需求
• 市場機會
• 新興市場
• 個人化醫療
• 市場挑戰
• 技術挑戰
• 監管和檢驗的複雜性

第4章 新興科技與發展

• 概述
• 關鍵要點
• 新興技術
• 基因組學
• 蛋白質體學
• 代謝體學
• 影像學
• 生物資訊學

第5章 收購、合作及授權協議

• 生物標記市場許可協議（2019-2025）
• 許可協議的定義和一般結構
• 估值和結算結構
• 生物標記市場許可協議分析（2019-2025）
• 生物標記市場收購（2019-2025）
• 收購的定義和一般結構
• 生物標記市場收購分析（2019-2025）
• 生物標記市場夥伴關係/合作（2019-2025）
• 合作的定義和整體結構
• 生物標記市場夥伴關係/協作分析（2019-2025）
• 生物標記市場交易的進一步分析
• 許可協議結構分析（2019-2025）
• 生物標記產業收購結構（2019-2025）
• 生物標記市場的合作夥伴結構（2019-2025）

第6章 生物標記專利格局

• 專利態勢亮點
• 專利審查

第7章 附錄

• 調查方法
• 資訊來源
• 簡稱
• 公司簡介
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BAYER AG
• BD
• BIOFOURMIS
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• BRUKER
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• MERCK KGAA
• QIAGEN
• REVVITY
• THERMO FISHER SCIENTIFIC INC.

This report provides an analysis of strategic transactions encompassing licensing, acquisitions and collaborations in the global biomarker market. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.

Report Scope

This report, Biomarker Deals: Terms, Value and Trends 2019-2025, offers a comprehensive analysis of strategic transactions, encompassing licensing, acquisitions and collaborations, in the global biomarkers industry. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.

The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.

In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.

Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.

Report Includes

• An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including a comprehensive analysis of deal structures and their potential values
• Coverage of significant companies in this study, trends and obstacles and other information affecting the development of the biomarker market
• Review of business terms and conditions of deals in the market, with focus on major trends in deal-making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
• Information essential to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
• Information about the main elements in licensing, acquisitions and partnership deals in the biomarker industry
• Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis, et al.
• Details on various types of biomarkers deals and milestone payments and their value in different deals
• Analysis of the patent landscape featuring biomarkers
• Profiles of the leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Classification of Biomarkers
• Examples of Biomarkers

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Incidence of Diseases
• Advances in Omics and Imaging Technologies
• Market Restraints
• Development Costs
• Need for Skilled Labor
• Market Opportunities
• Emerging Markets
• Personalized Medicine
• Market Challenges
• Technical Challenges
• Regulatory and Validation Complexity

Chapter 4 Emerging Technologies and Developments

• Overview
• Key Takeaways
• Emerging Technologies
• Genomics
• Proteomics
• Metabolomics
• Imaging
• Bioinformatics

Chapter 5 Acquisitions, Collaborations, and Licensing Deals

• Licensing Deals in the Biomarker Market, 2019 to 2025
• Definition and General Structure of Licensing Deals
• Valuation and Payment Structure
• Analysis of Licensing Deals in the Biomarker Market, 2019 to 2025
• Acquisitions in the Biomarker Market, 2019 to 2025
• Definition and General Structure of Acquisitions
• Analysis of Acquisitions in the Biomarker Market, 2019 to 2025
• Partnerships/Collaborations in Biomarker Market, 2019 to 2025
• Definition and General Structure of Collaborations
• Analysis of Partnerships/Collaborations in the Biomarkers Market, 2019 to 2025
• Further Analysis of Deals in the Biomarker Market
• Analysis of Structure of Licensing Deals, 2019 to 2025
• Structure of Acquisitions in the Biomarker Industry, 2019 to 2025
• Structure of Collaborations in the Biomarker Market, 2019 to 2025

Chapter 6 Biomarker Patent Landscape

• Patent Landscape Takeaways
• Patent Review

Chapter 7 Appendix

• Methodology
• Information Sources
• Abbreviations
• Company Profiles
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BAYER AG
• BD
• BIOFOURMIS
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• BRUKER
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• MERCK KGAA
• QIAGEN
• REVVITY
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Biomarker Licensing Deals, Acquisitions and Partnerships, by Type, 2021-2025
• Table 1 : Categories of Biomarkers
• Table 2 : Examples of Biomarkers
• Table 3 : Forms of Payment in Licensing Deals
• Table 4 : Number of Biomarker Licensing Deals in Biotech Sectors, 2019-2025
• Table 5 : Biomarker Licensing Deals, 2019-2025
• Table 6 : Number of Biomarker Licensing Deals in Pathological Sectors, 2019-2025
• Table 7 : Goals of Biomarker Licensing Deals, 2019-2025
• Table 8 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Table 9 : Number of Biomarker Acquisitions in Biotech Sectors, 2019-2025
• Table 10 : Biomarker Acquisitions, 2019-2025
• Table 11 : Number of Biomarker Acquisitions in Different Pathological Sectors, 2019-2025
• Table 12 : Goals of Biomarker Acquisitions, 2019-2025
• Table 13 : Number of Biomarker Collaborations in Biotech Sectors, 2019-2025
• Table 14 : Partnerships/Collaborations in the Biomarker Market, 2019-2025
• Table 15 : Number of Biomarker Collaborations in Pathological Sectors, 2019-2025
• Table 16 : Goals of Biomarker Collaborations, 2019-2025
• Table 17 : Up-Front Payments in Licensing Deals in the Biomarker Market, 2019-2025
• Table 18 : Milestone and Royalty Payments in Licensing Deals, 2019-2025
• Table 19 : Termination Conditions in Licensing Deals, 2019-2024
• Table 20 : Value of Biomarker Licensing Deals Worldwide, 2021-2025
• Table 21 : Acquisitions in the Biomarker Industry, 2020-2024
• Table 22 : Global Value of Biomarker Acquisitions, 2021-2025
• Table 23 : Up-Front Payments and Total Value in Collaboration Deals, 2019-2025
• Table 24 : Percentage of Up-Front Payments from Total Value in Collaborations, 2019-2025
• Table 25 : Milestones and Royalty Payments in Collaborations in the Biomarker Market, 2019-2025
• Table 26 : Number of Patents and Patent Applications Filed for Biomarkers, by Year, 2019-2024
• Table 27 : Patents and Patent Applications Filed for Biomarkers, 2019-2024
• Table 28 : Number of Patents and Patent Applications for Biomarkers, by Company, 2019-2024
• Table 29 : Information Sources for this Report
• Table 30 : Abbreviations Used in this Report
• Table 31 : Abbott: Company Snapshot
• Table 32 : Abbott: Financial Performance, FY 2023 and 2024
• Table 33 : Abbott: Product Portfolio
• Table 34 : Abbott: News/Key Developments, 2023 and 2024
• Table 35 : Agilent Technologies Inc.: Company Snapshot
• Table 36 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
• Table 37 : Agilent Technologies Inc.: Product Portfolio
• Table 38 : Agilent Technologies Inc.: News/Key Developments, 2023 and 2024
• Table 39 : Bayer AG: Company Snapshot
• Table 40 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 41 : Bayer AG: Product Portfolio
• Table 42 : Bayer AG: News/Key Developments, 2024
• Table 43 : BD: Company Snapshot
• Table 44 : BD: Financial Performance, FY 2023 and 2024
• Table 45 : BD: Product Portfolio
• Table 46 : BD: News/Key Developments, 2024
• Table 47 : Biofourmis: Company Snapshot
• Table 48 : Biofourmis: Product Portfolio
• Table 49 : Biofourmis: News/Key Developments, 2020 and 2024
• Table 50 : bioMerieux: Company Snapshot
• Table 51 : bioMerieux: Financial Performance, FY 2023 and 2024
• Table 52 : bioMerieux: Product Portfolio
• Table 53 : bioMerieux: News/Key Developments, 2024
• Table 54 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 55 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
• Table 56 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 57 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024
• Table 58 : Bruker: Company Snapshot
• Table 59 : Bruker: Financial Performance, FY 2023 and 2024
• Table 60 : Bruker: Product Portfolio
• Table 61 : Bruker: News/Key Developments, 2023
• Table 62 : Danaher Corp.: Company Snapshot
• Table 63 : Danaher Corp.: Financial Performance, FY 2023 and 2024
• Table 64 : Danaher Corp.: Product Portfolio
• Table 65 : Danaher Corp.: News/Key Developments, 2022-2024
• Table 66 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 67 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 68 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 69 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
• Table 70 : Illumina Inc.: Company Snapshot
• Table 71 : Illumina Inc.: Financial Performance, FY 2023 and 2024
• Table 72 : Illumina Inc.: Product Portfolio
• Table 73 : Illumina Inc.: News/Key Developments, 2024
• Table 74 : Merck KGaA: Company Snapshot
• Table 75 : Merck KGaA: Financial Performance, FY 2023 and 2024
• Table 76 : Merck KGaA: Product Portfolio
• Table 77 : Merck KGaA: News/Key Developments, 2024
• Table 78 : Qiagen: Company Snapshot
• Table 79 : Qiagen: Financial Performance, FY 2023 and 2024
• Table 80 : Qiagen: Product Portfolio
• Table 81 : Qiagen: News/Key Developments, 2023 and 2024
• Table 82 : Revvity: Company Snapshot
• Table 83 : Revvity: Financial Performance, FY 2023 and 2024
• Table 84 : Revvity: Product Portfolio
• Table 85 : Revvity: News/Key Developments, 2022 and 2023
• Table 86 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 87 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 88 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 89 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024

List of Figures

• Figure 1 : Market Dynamics Snapshot
• Figure 2 : Share of Biomarker Licensing Deals, by Therapeutic Area, 2019-2025
• Figure 3 : Share of Biomarker Licensing Deals, by Goal, 2019-2025
• Figure 4 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Figure 5 : Share of Biomarker Acquisitions in Pathological Sectors, 2019-2025
• Figure 6 : Share of Biomarker Acquisitions, by Goal, 2019-2025
• Figure 7 : Share of Biomarker Collaborations in Biotech Sectors, by Year, 2019-2025
• Figure 8 : Share of Biomarker Collaborations in Pathological Sectors, 2019-2025
• Figure 9 : Share of Biomarker Collaborations, by Goal, 2019-2025
• Figure 10 : Share of Collaborations Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
• Figure 13 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 14 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 15 : Bayer AG: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Bayer AG: Revenue Share, by Country/Region, FY 2024
• Figure 17 : BD: Revenue Share, by Business Unit, FY 2024
• Figure 18 : BD: Revenue Share, by Country/Region, FY 2024
• Figure 19 : bioMerieux: Revenue Share, by Business Unit, FY 2024
• Figure 20 : bioMerieux: Revenue Share, by Country/Region, FY 2024
• Figure 21 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 22 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 23 : Bruker: Revenue Share, by Business Unit, FY 2024
• Figure 24 : Bruker: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Danaher Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 26 : Danaher Corp.: Revenue Share, by Country/Region, FY 2024
• Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 28 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 29 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 30 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 31 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
• Figure 32 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
• Figure 33 : Qiagen: Revenue Share, by Business Unit, FY 2024
• Figure 34 : Qiagen: Revenue Share, by Country/Region, FY 2024
• Figure 35 : Revvity: Revenue Share, by Business Unit, FY 2024
• Figure 36 : Revvity: Revenue Share, by Country/Region, FY 2024
• Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
• Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024